Abstract: Disclosed are biomarkers for preeclampsia including elevated levels of free hemoglobin, including free fetal haemoglobin and the ratio of free fetal hemoglobin to total free hemoglobin. Also disclosed are methods of treating preeclampsia using a therapeutic agent that reduces free circulating hemoglobin levels.
Abstract: Medical use of alpha-1-microglobulin (A1M) in the treatment or prophylaxis of diseases wherein oxidative stress is a responsible factor in the progress of the disease. Notably, the present invention relates to the medical use of alpha-1-microglobulin in the treatment or prophylaxis of diseases or conditions associated with the presences of free radicals and/or free haemoglobin in the subject.
Type:
Grant
Filed:
July 17, 2009
Date of Patent:
July 16, 2019
Assignee:
A1M PHARMA AB
Inventors:
Bo Åkerström, Stefan Hansson, Martin Lennarth Olsson, Magnus Gram
Abstract: The present invention relates to biomarkers for preeclampsia as well as treatment of this disease. In particular, the invention relates to methods for diagnosis or aiding in the diagnosis of preeclampsia of a pregnant female mammal to detect elevated levels of free haemoglobin, particularly free fetal haemoglobin. This facilitates and makes possible early diagnosis and clinical intervention when a preeclamptic condition is found. In addition, the invention relates to a method to treat female mammals with preeclampsia with the purpose to reverse the pathological conditions associated with this disease.
Abstract: This invention relates to ?1-microglobulin (A1M) for use in the diagnosis or treatment of malignancies requiring radionuclide diagnostics (RD), radionuclide therapy (RNT) or radioimmunotherapy (RIT), respectively, wherein A1M is used as a co-treatment to RD, RNT or RIT.
Type:
Application
Filed:
February 25, 2016
Publication date:
August 30, 2018
Applicant:
A1M PHARMA AB
Inventors:
Bo Akerstrom, Sven-Erik STRAND, Magnus Göran GRAM, Amanda Thuy TRAN
Abstract: The present invention relates to the use of hemopexin, free, non-cell bound fetal hemoglobin and alpha-1-micro-globulin as markers for preeclampsia.
Type:
Application
Filed:
March 16, 2016
Publication date:
March 15, 2018
Applicant:
A1M Pharma AB
Inventors:
Stefan HANSSON, Bo AKERSTRÖM, Magnus Göran GRAM
Abstract: The present invention relates to biomarkers for preeclampsia as well as treatment of this disease. In particular, the invention relates to methods for diagnosis or aiding in the diagnosis of preeclampsia of a pregnant female mammal to detect elevated levels of free haemoglobin, particularly free fetal haemoglobin. This facilitates and makes possible early diagnosis and clinical intervention when a preeclamptic condition is found. In addition, the invention relates to a method to treat female mammals with preeclampsia with the purpose to reverse the pathological conditions associated with this disease.
Abstract: The present invention relates to biomarkers for preeclampsia as well as treatment of this disease. In particular, the invention relates to methods for diagnosis or aiding in the diagnosis of preeclampsia of a pregnant female mammal to detect elevated levels of free haemoglobin, particularly free fetal haemoglobin. This facilitates and makes possible early diagnosis and clinical intervention when a preeclamptic condition is found. In addition, the invention relates to a method to treat female mammals with preeclampsia with the purpose to reverse the pathological conditions associated with this disease.